YZYuqi Zhang

Yuqi Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuqi Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Can integrated care interventions strengthen primary care and improve outcomes for patients with chronic diseases? A systematic review and meta-analysis

    by Yuqi Zhang, Jonathan Stokes, Laura Anselmi, Peter Bower, Jin Xu

    An increasing number of people live with chronic disease or multi-morbidity. Current consensus is that their care requires an integrated model bringing different professionals together to provide person-centred care. Although primary care has a central role in managing chronic disease, and integration may be important in strengthening this role, previous research has shown insufficient attention to the relationships between primary care and integration. This review summarizes primary care involvement in integrated care interventions and assesses the effect of those interventions on a range of measures of primary care functions and wider outcomes. We searched Medline and Embase using terms for “integrated care”, “chronic disease” and “multimorbidity”. We included integrated care interventions involving different levels of care organizations or different care sectors. Risk of bias was appraised, and the contents of integrated care interventions assessed using the Sustainable intEgrated care modeLs for multi-morbidity: delivery, FInancing and performancE (SELFIE) conceptual framework. Effectiveness of integrated care interventions was assessed using meta-analysis of primary care functions (access, continuity, comprehensiveness and coordination) and wider outcomes (patient health and mortality, hospital admissions and costs). Sub-group analyses were conducted for different types of primary care involvement. From 17,752 studies screened, 119 studies on integrated care were identified, of which 69 interventions (58%) involved primary care. Meta-analyses showed significant beneficial effects on two measures of primary care function: access (effect size: 0.17, 95% CI 0.05–0.29) and continuity (effect size: 0.32, 95% CI 0.14–0.50). For wider outcomes, the only statistically significant effect was found on costs (effect size: 0.02, 95% CI 0.02–0.03). Integrated care interventions involving primary care can have positive effects on strengthening primary care functions, but these benefits do not necessarily translate consistently to wider outcomes.


  • Open Access

    1168 Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMabTM mice

    by Jun Du, Wanbo Tang, Xin Jiao, Limin Zhao, Pengfei Du, Yuqi Zhang, Yue Zhang, Han Chen, Jian Bao, Aijing Niu, et al.

    Background Mutations in the small GTPase protein KRAS drive several cancers, owing to accelerated growth and differentiation phenotypes resulting from altered GDP-GTP exchange and GTP hydrolysis rates. As targeting RAS proteins with traditional drug modalities has proved to be challenging, new therapeutic strategies are needed. Here, we generated and screened TCR-mimic antibody hits targeting the mutant KRAS G12V peptide/HLA complex, as the majority of KRAS mutations occur at this residue.1 Methods HLA-transgenic RenMice™ were immunized with KRAS G12V/HLA-A0301 or KRAS G12V/HLA-A1101 peptide-MHC (pMHC) complexes. The specificity of antibody hits recovered from the mice, as well as a positive control antibody previously described,2 was tested on HLA-A overexpressing cells in the context of various KRAS peptides by flow cytometry. Positive hits were assessed for heavy and light chain germline gene usage and CDR3 length, and KD values were measured. To assess specificity of the antibodies, binding of two candidate antibody hits to other peptide and/or HLA complexes were tested. Alanine scanning substitutions of the KRAS G12V peptide were also performed to identify the residues critical for TCR-mimic antibody recognition. Killing of HLA-A0301+ cells with KRAS G12V or wildtype KRAS by TCR-mimic antibody candidate 2 conjugated to a CD3-targeting antibody was subsequently measured (by LDH activity) in the context of human T cells. Results We identified TCR-mimic antibodies with specificity for KRAS G12V residues 7–16 complexed with HLA-A0301 or HLA-A1101 by flow cytometry. KRAS G12V/HLA-A1101 and KRAS G12V/HLA-A0301 antibody hits exhibited varying degrees of germline gene diversity and CDR3 length, with the majority of KRAS G12V/HLA-A0301 antibodies exhibiting higher affinity than the positive control. KRAS G12V/HLA-A0301 antibodies specifically bound HLA-A0301 overexpressing cells pulsed with KRAS G12V decamer peptide in a dose-dependent manner, but did not bind KRAS G12C, G12D, WT peptide or unpulsed controls. Furthermore, KRAS G12V/HLA-A0301 antibodies did not bind HLA-A1101 overexpressing cells loaded with KRAS mutant or WT peptides, or HLA-A0301 overexpressing cells loaded with off-target peptide. Alanine substitutions revealed that residue V6 of KRAS G12V was required for antibody binding. Cytotoxicity assays demonstrate specificity of KRAS G12V/HLA-A0301 antibody for KRAS G12V+/HLA-A0301+ cells. Conclusions Using our novel fully human HLA-transgenic RenMice, we have successfully generated and screened TCR-mimic antibodies specific for KRAS G12V/HLA-A0301 pMHC or KRAS G12V/HLA-A1101 pMHC complexes for further preclinical investigation. References Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov 2020;19:902. https://doi.org/10.1038/s41573–020-0089–1 Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021 Mar 1;6(57):eabd5515. doi: 10.1126/sciimmunol.abd5515. PMID: 33649101; PMCID: PMC8141259. Ethics Approval All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Biocytogen Beijing Co., Ltd.